Expertise in
11
conditions

Dr. Geoffrey R. Oxnard

Oncology
Boston University Radiation Oncology Inc.
830 Harrison Ave, 
Boston, MA 
Accepting New Patients
Expertise in
11
conditions
Boston University Radiation Oncology Inc.
830 Harrison Ave, 
Boston, MA 

Overview

Geoffrey Oxnard is an Oncologist practicing medicine in Boston, Massachusetts.

Dr. Oxnard is highly rated in 11 conditions, according to our data. His clinical expertise encompasses EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 201 peer reviewed articles and participating in 23 clinical trials. Dr. Oxnard is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MA

Hospital Affiliations

Boston Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Boston University Radiation Oncology Inc.
830 Harrison Ave, Boston, MA 02118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).
A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2026
Intervention Type: Drug
Study Drugs: AZD9291+AZD6094, AZD9291+Selumetinib, AZD9291+MEDI4736, AZD6094
Study Phase: Phase 1
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 30, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
Enrollment Status: Active_not_recruiting
Publish Date: April 27, 2026
A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 2
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
View 9 Less Clinical Trials

201 Total Publications

Germline determinants of risk and molecular subtype in young-onset lung cancer.
Germline determinants of risk and molecular subtype in young-onset lung cancer.
Journal: medRxiv : the preprint server for health sciences
Published: July 17, 2026
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.0 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Abramson is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Abramson is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Abramson is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (1.7 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Davids is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Davids is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Tissue Biopsy. Dr. Davids is currently accepting new patients.

Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Office

55 Fruit St, 
Boston, MA 
 (2.0 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edwin Choy is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Choy is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Osteosarcoma. Dr. Choy is currently accepting new patients.

Frequently Asked Questions about Dr. Geoffrey R. Oxnard

How do I make an appointment with Dr. Geoffrey R. Oxnard?

You can book an appointment with Dr. Geoffrey R. Oxnard by calling their office at 617-638-6428. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Geoffrey R. Oxnard a top-rated expert for EGFR Positive Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Geoffrey R. Oxnard is classified as an Elite expert for EGFR Positive Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Geoffrey R. Oxnard specialize in?

While Dr. Geoffrey R. Oxnard is a Oncology, they have specific expertise in EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Geoffrey R. Oxnard participate in research or clinical trials?

Yes. Dr. Geoffrey R. Oxnard has published 201 articles and abstracts on conditions like EGFR Positive Lung Cancer. You can view a list of Dr. Geoffrey R. Oxnard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Geoffrey R. Oxnard accept my insurance?

Dr. Geoffrey R. Oxnard accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 617-638-6428 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oxnard's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile